REG - RTW Biotech Opp. - Additional Investment in Numab Therapeutics

RTW Biotech OpportunitiesAnnouncement

14/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250114:nRSN1598Ta&default-theme=true

RNS Number : 1598T  RTW Biotech Opportunities Ltd  14 January 2025

LEI: 549300Q7EXQQH6KF7Z84

14 January 2025

RTW Biotech Opportunities Ltd

Additional Investment in Numab Therapeutics

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed
investment company focused on identifying transformative assets with high
growth potential across the life sciences sector, is pleased to note an
additional investment in the Series C extension of Numab Therapeutics
("Numab"), a Swiss clinical stage biotech advancing a proprietary pipeline of
multi-specific antibodies in immunology and oncology.

 

Numab announced the completion of its CHF 50 million (~US$55m) Series C
extension, in which the Company participated alongside other investment
vehicles managed by RTW Investments, LP (the "Investment Manager"). The
extension brought total Series C funding to CHF 180 million (~US$196m). The
funds will be used to support the advancement of multiple potentially
first-in-class and best-in-class programs into clinical development. The
Company first invested in Numab's original Series C round in May of 2021.

 

Roderick Wong, Managing Partner and CIO at the Investment Manager said, "We
are delighted to continue supporting Numab Therapeutics. Their innovative
approach to developing multi-specific antibodies is particularly promising,
and we believe that their groundbreaking research and development efforts hold
great potential for transforming autoimmune and cancer treatments. Following
J&J's announcement last summer to acquire Numab subsidiary, Yellow Jersey
Therapeutics, we are optimistic that our continued partnership and this latest
financing round will contribute to other significant advancements in
immunology and oncology therapeutics."

 

The full text of the announcement can be accessed at https://www.numab.com
(https://www.numab.com/wp-content/uploads/250109_PR_Numab-SeriesC-Top-up-Financing.pdf)
.

 

  For Further Information

 RTW Investments, LP                                                      +44 20 7959 6361
 Woody Stileman, Managing Director, Business Development                  biotechopportunities@rtwfunds.com (mailto:biotechopportunities@rtwfunds.com)

 Krisha McCune, Director, Investor Relations

 Cadarn Capital (PR & Communications/Distribution & IR Partner)           +44 79 8418 4461
                                                                           Lucy@cadarncapital.com (mailto:Lucy@cadarncapital.com)

 Lucy Clark (PR)

 David Harris (Distribution)                                              +44 73 6888 3211

                                                                          david@cadarncapital.com

 Deutsche Numis (Joint Corporate Broker)                                  +44 20 7260 1000

 Freddie Barnfield

 Nathan Brown

 Euan Brown

 BofA Securities (Joint Corporate Broker)                                 +44 20 7628 1000

 Edward Peel

 Alex Penney

 Elysium Fund Management Limited                                           +44 14 8170 3100

 Joanna Duquemin Nicolle, Chief Executive Officer

 Sadie Morrison, Managing Director

 Morgan Stanley Fund Services USA LLC                                     +1 914 225 8885

 

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

**********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAPFDFFNSEFA